ASNDAscendis Pharma A/S
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Very Bullish
91
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest Expense
Interest & Investment Income
Other Income / (Expense), net
Earnings History
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Very Bullish
91
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest Expense
Interest & Investment Income
Other Income / (Expense), net
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
Jan M. Mikkelsen
Location
N/A, N/A
Exchange
Nasdaq
Website
https://ascendispharma.com
Summary
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Company Info
CEO
Jan M. Mikkelsen
Location
N/A, N/A
Exchange
Nasdaq
Website
https://ascendispharma.com
Summary
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Be the first to know. We'll notify you when AI insights for ASND go live.
Community Research
Research from investors like you
Be the first to share your analysis on ASND
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Ascendis Pharma gets FDA approval for achondroplasia drug, challenging BioMarin's monopoly
Ascendis Pharma gets FDA approval for achondroplasia drug, challenging BioMarin's monopoly
finance.yahoo.com
| Ascendis wins FDA approval of dwarfism drug
No more topics to show